Choline-containing research compound · Fact sheet
Citicoline
Also known as CDP-choline
Citicoline is a choline-containing compound studied for brain injury and cognition. Two large clinical trials found no improvement in their stroke or traumatic-brain-injury populations; those results limit broad brain-repair claims.
What is Citicoline?
Citicoline is involved in phospholipid metabolism. A normal cellular role does not establish benefit from extra intake.
Acute stroke, traumatic brain injury and healthy-person cognition are separate clinical questions.
Benefits & claims
Interest in Citicoline spans cognition and sleep, specific medical conditions. Study findings apply to the named formulation and population.
What the evidence supports
- ICTUS found similar global recovery with citicoline and placebo.
- COBRIT found no significant 90- or 180-day benefit.
- Smaller mechanistic or task-based findings cannot override these negative disease-specific trials.
Research areas
- Formulation-specific human outcomes
- Mechanistic research
Dosage & frequency
Human study contextThis is an exposure from a named human study, not a generally established treatment or enhancement regimen.
COBRIT traumatic-brain-injury trial
1,213 patients with complicated mild, moderate or severe traumatic brain injury
- Amount
- 2,000 mg total daily
- Frequency
- Daily for 90 days
- Route studied or labeled
- Oral
Enteral or oral administration under trial care. Functional and cognitive outcomes did not improve versus placebo; the trial does not establish brain-repair treatment.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Citicoline is involved in phospholipid metabolism. A normal cellular role does not establish benefit from extra intake.
Formulation differences
- Acute stroke, traumatic brain injury and healthy-person cognition are separate clinical questions.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Side effects & risks
- The stroke trial did not find a significant safety difference, but this does not establish universal or long-term safety.
- Effects with multiple cholinergic or neurologic treatments and different formulations need specific assessment.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceICTUS randomized 2,298 stroke patients and stopped for futility. COBRIT randomized 1,213 people with traumatic brain injury and found no functional or cognitive advantage.
Studies
Large negative acute-stroke trial.
Large negative traumatic-brain-injury trial.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved Citicoline drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).
- Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT).
- FDA: what approval means for supplements
Open questions
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Summary
Smaller mechanistic or task-based findings cannot override these negative disease-specific trials.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedCiticoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).
Large negative acute-stroke trial.
- pubmedEffect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT).
Large negative traumatic-brain-injury trial.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.